As ondas de calor relatadas no climatério apresentam alta prevalência e afetam de forma significativa a qualidade de vida das mulheres acometidas. O climatério pode cursar com obesidade, hipertensao, diabetes mellitus tipo II e outros fatores de risco cardiovascular, que, em conjunto, compõem a síndrome metabólica, e que pode estar relacionada à maior ocorrência de ondas de calor. O presente estudo tem por objetivo estimar a prevalência de ondas de calor, bem como verificar sua relacao com a síndrome metabólica, em mulheres no climatério residentes em Pindamonhangaba, SP. Assim, em estudo transversal realizado à partir de um banco de dados de um projeto denominado PROSAPIN (PROjeto de SAúde de PINdamonhangaba) foram analisadas 900 mulheres de 35 a 65 anos - período conceituado como climatério (Notelovitz 1988). Todas as participantes foram avaliadas por meio da escala de Kupperman para quantificar os sintomas climatéricos e pelos critérios do ATPIII, para firmar o diagnóstico de síndrome metabólica. A prevalência de ondas de calor foi de 53,89% (IC95%: 50,62% - 57,15%). Por meio de um modelo de Regressao de Poisson múltipla, ainda se constatou nítida associacao da presenca de ondas de calor com síndrome metabólica, insonia, depressao, estresse e raca negra e parda. Em conclusao, as ondas de calor apresentaram alta prevalência na populacao estudada e se associaram a distúrbios emocionais, à raca e à síndrome metabólica. / Vasomotor symptoms or hot flushes are very prevalent in the climacteric period and significantly worsen the quality of life of the women affected. Climacteric can occur with obesity, hypertension, type II diabetes mellitus and other cardiovascular risk factors, which, together, represents the metabolic syndrome, that appear to be related to a higher occurrence of hot flushes. The present study aims to estimate the prevalence of hot flashes, as well as to verify its relationship with the metabolic syndrome, among climacteric women resident in Pindamonhangaba, SP. Thus, a cross-sectional study from a database of a project called PROSAPIN (PINdamonhangaba`s Health Project) analyzed 900 women from 35 to 65 years-old - a period known as climacteric (Notelovitz 1988). All participants were evaluated through the Kupperman scale to quantify the climacteric symptoms and through the ATPIII criteria, to establish the diagnosis of metabolic syndrome. The prevalence of hot flushes was 53,89% (CI95%: 50,62% - 57,15%), and, by a multiple Poisson regression model, it was observed a clear association between the presence of hot flushes and metabolic syndrome, insomnia, depression, anxiety and afrodescendence. In conclusion, the hot flushes presented high prevalence in the study population and were associated with emotional disorders, ethnicity and to the metabolic syndrome.

A Síndrome Metabólica (SM) é um transtorno complexo representado por um conjunto de fatores de risco cardiovascular, usualmente relacionados à deposição central de gordura e à resistência à insulina. Hipertensos com SM apresentam alta prevalência de lesões de órgãos-alvo e amplificação dos riscos cardiovasculares, com impacto prognóstico adverso. Este estudo descritivo, desenvolvido na Unidade Mista de Saúde de um município do interior paulista, teve como objetivo identificar os componentes de SM entre portadores de hipertensão arterial sistêmica e comparar a ocorrência dos fatores de risco associados à SM na população hipertensa e normotensa. Os aspectos adotados para a definição de SM foram os definidos pelo National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III). As variáveis investigadas foram os dados sócio-demográficos, os valores de pressão arterial, cintura abdominal, glicemia, HDL colesterol e triglicerídeos plasmáticos. As análises descritivas, com cálculo de freqüências absolutas e porcentagens, foram realizadas por meio do pacote estatístico SPSS, versão 15.0. Utilizou-se o teste t de Student para comparações das médias dos dados quantitativos. Os resultados foram expressos como médias ± erros padrões das médias, e as diferenças consideradas estatisticamente significantes para p<0,05. A amostra foi composta por 261 participantes, classificados em normotensos (35,6%) e hipertensos (64,4%). A maioria dos participantes é do sexo feminino (70,5%), natural do estado de São Paulo (72,4%), de cor branca (78,5%), analfabeta funcional (49,8%), vive com companheiro (66,7%) e possui antecedentes familiares de doenças cardiovasculares (75,1%). A média de idade foi de 49 anos para o grupo normotenso e 58,8 anos para o grupo hipertenso. A SM esteve presente em 119 indivíduos, representando uma prevalência global de 45,6%. Identificamos a presença de SM em 60,7% dos hipertensos e em 18,3% dos normotensos. Comparado ao grupo normotenso, os portadores de hipertensão arterial apresentam, além da elevação da pressão arterial sistólica (p<0,001) e diastólica (p<0,001), diferença significante nos valores de circunferência abdominal (p<0,001), glicose (p<0,05) e triglicérides (p<0,05). Valor aumentado de circunferência abdominal foi o fator prevalente na amostra global e entre os portadores de hipertensão arterial. Em ambos os grupos, indivíduos do sexo feminino apresentam maior percentual de ocorrência de todos os componentes da SM. Considerando a combinação dos componentes da SM, ambos os grupos apresentaram como elementos mais frequentes baixos níveis de HDL-C + hipertrigliceridemia + obesidade abdominal. Conclui-se que a frequência dos riscos cardiometabólicos associados à SM é maior na presença de doença hipertensiva. Indivíduos que apresentam SM compartilham aspectos fisiopatológicos de alto risco para o desenvolvimento de doenças cardiovasculares. / Metabolic syndrome (MS) is a complex disorder represented by a set of cardiovascular risk factors. It is commonly associated with central adiposity and insulin resistance. Hypertensive patients with MS have high prevalence of target organ damage and amplification of cardiovascular risks, with adverse prognostic impact. This descriptive study, developed in the Joint Health Unit in an interior city, aimed to identify the components of MS among patients with hypertension and to compare the occurrence of risk factors associated with MS in normotensive and hypertensive population. Aspects adopted for the definition of MS were defined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III). The variables were the socio-demographic data, the values of blood pressure, waist circumference, blood glucose, plasma HDL cholesterol and triglycerides. The descriptive analysis, with calculation of absolute frequencies and percentages, were performed using the statistical package SPSS, version 15.0. We used the Student t test for comparisons of the average figures. Results were expressed as means ± standard errors of averages and differences considered statistically significant at p <0.05. The sample comprised 261 participants, divided into normotensive (35.6%) and hypertension (64.4%). Most participants were female (70.5%), a native of São Paulo (72.4%), white (78.5%), functionally illiterate (49.8%), lives with partner (66.7%) and have a family history of cardiovascular disease (75.1%). The average age was 49 years for the normotensive group and 58.8 years for the hypertensive group. MS was present in 119 individuals, representing an overall prevalence of 45.6%. Identified the presence of SM in 60.7% of hypertensive patients and in 18.3% of normotensive individuals. Compared to the normotensive group, patients with hypertension present besides the elevation of systolic blood pressure (p <0.001) and diastolic (p<0.001), significant differences in the values of waist circumference (p<0.001), glucose (p<0,05) and triglycerides (p<0.05). Increased value of waist circumference was the prevalent factor in the total sample and among patients with hypertension. In both groups, females have a higher percentage of occurrence of all components of MS. Considering the combination of components of MS, both groups presented as the most frequent low HDL-C + hypertriglyceridemia + obesity. It is concluded that the prevalence of cardiometabolic risk associated with MS is higher in the presence of hypertensive disease. Individuals that have SM share pathophysiological features of high risk for developing cardiovascular disease.

Introdução São escassos os estudos pertinentes à caracterização da prevalência e de fatores associados à síndrome metabólica na transição e após a menopausa. Ademais, a síndrome metabólica suscita diversos agravos à saúde da mulher com sérias repercussões para a Saúde Pública. Objetivos - Estimar a prevalência da síndrome metabólica das mulheres na transição e após a menopausa e caracterizar os fatores associados à síndrome metabólica. Métodos Em estudo transversal foram selecionadas aleatoriamente 875 mulheres de 35 a 65 anos do Programa de Saúde da Família de Pindamonhangaba, São Paulo. A variável dependente analisada foi a síndrome metabólica, definida pelo National Cholesterol Education Program Adult Treatment Panel III e pela International Diabetes Federation. Os fatores associados, condições de saúde e hábitos de vida, foram questionados por meio de inquérito populacional e avaliados por medidas antropométricas. Resultados Foram investigadas 515 mulheres com idade média de 47,6 e desvio padrão de 8,1 anos. A média de idade da menopausa foi 45,8 anos (desvio padrão de 6,8) e a maior parte delas estava na pré menopausa. A prevalência da síndrome metabólica foi de 51,9% segundo a International Diabetes Federation e 42,6% pelo National Cholesterol Education Program Adult Treatment Panel III. O achado metabólico mais freqüente foi a circunferência abdominal, seguida de HDL colesterol, triglicérides, hipertensão e diabetes mellitus. Os fatores associados potenciais para a síndrome metabólica foram: idade de 45 a 54 anos e mais evidente para 55 a 65 anos, hiperuricemia e características sugestivas de apnéia do sono. O tempo maior que 5 anos na escola foi fator protetor para a síndrome metabólica. Conclusão A prevalência da síndrome metabólica foi alta e os fatores associados foram idade, hiperuricemia, características sugestivas de apnéia do sono e tempo de estudo. / Introduction The studies of prevalence and associated factors in the transition and postmenopause are rare. Furthermore, the metabolic syndrome may have serious implications for women\'s health. Objectives Estimate the prevalence of the metabolic syndrome of women in the transition and postmenopause and evaluate the associated factors to the metabolic syndrome. Methods In a cross-sectional study there were selected randomly 875 women aged 35 - 65 years of the Health Family Program of the city of Pindamonhangaba, São Paulo. The dependent variable was the metabolic syndrome, classified by the National Cholesterol Education Program Adult Treatment Panel III and by the International Diabetes Federation. The associated factors, health conditions and life habits, were evaluated through a questionnaire and anthropometrics measures. Results There were investigated 515 women with average age of 47.6 years and standard deviation of 8.1 years. The average age of menopause was 45.8 years and most of them were in premenopause. The prevalence of the metabolic syndrome was 51.9% according to the International Diabetes Federation and 42.6% to the National Cholesterol Education Program Adult Treatment Panel III. The abdominal obesity was the most frequent metabolic result found followed by HDL colesterol, triglycerides, hypertension and diabetes. The potential associated factors for the metabolic syndrome were: age between 45-54 being more evident for 55- 65 years old, hyperuricemia and risks of sleep apnea. The time at school bigger than 5 years reduced this risk. Conclusion The prevalence of metabolic syndrome was high and the associated factors were age, hyperuricemia, risk of sleep apnea and years of study.

L’utilisation d’antagonistes du récepteur aux minéralocorticoïdes (ARM) a prouvé son efficacité dans le traitement de l’insuffisance cardiaque (IC). Un des facteurs de risque majeur de l’IC, le syndrome métabolique (SMet), est également associé à une production augmentée d’aldostérone et une activation excessive de son récepteur. Dans ce contexte, nous avons émis l’hypothèse que l’utilisation des ARM pouvait être appliquée pour cibler les facteurs de risques du SMet et prévenir la progression subséquente vers l’IC. Dans ce projet, des rats Spontanément Hypertendus et développant une IC (rats SHHF) portant ou non une mutation du récepteur de la leptine (« cp ») conduisant à un SMet (respectivement SHHFcp/cp et SHHF+/+) ont été utilisés comme modèle expérimental. Les animaux ont reçu soit un placebo soit le traitement ARM (Eplérénone, Eplé) dès l’âge de 1.5 à 12.5 mois et leurs paramètres métaboliques et cardiovasculaires ont été régulièrement évalués. Les fonctions moléculaires altérées dans le coeur et le tissu adipeux lors du développement du SMet et la progression de l’IC, ainsi que celles modulées par l’action de l’Eplé ont été caractérisées par l’analyse du transcriptome et miRNome des animaux. Nos résultats montrent que les rats SHHFcp/cp développent à 12.5 mois une hypertrophie cardiaque excentrique associée à une dilatation du ventricule gauche (VG) et une fraction d’éjection diminuée comparés aux SHHF+/+. Alors que l’Eplé ne modifie pas les paramètres métaboliques et cardiovasculaires des SHHF+/+, Les rats Eple-SHHFcp/cp présentent une moindre prise de masse corporelle ainsi qu’une moindre dyslipidémie. Sans effet sur la pression artérielle (PA), ni le transcriptome et miRNome adipeux, les animaux SHHFcp/cp traités présentent en outre une moindre dilatation et hypertrophie de leur VG, une fraction d’éjection, un temps de relaxation isovolumique et un ratio E/A plus élevés. Les analyses du transcriptome et miRNome cardiaques révèlent que l’Eplé induit une diminution significative de l’expression de gènes impliqués dans le remodelage et l’inflammation myocardiques ainsi qu’une augmentation de l’expression de gènes relatifs à l’oxydation des acides gras dans le coeur. L’intégration et l’exploration bioinformatique des profils d’expression du transcriptome et du miRNome ont permis d’établir des réseaux de régulation de l’expression génique potentiellement impliqués dans les mécanismes physiopathologiques à l’oeuvre chez les rats SHHF obèses et dans ceux impactés par le traitement. Dans leur ensemble, nos données montrent que l’initiation d’un traitement ARM lors du développement du SMet permet d’atténuer l’obésité et la dyslipidémie et d’améliorer les paramètres de structure et fonction cardiaque. De façon intéressante, ces effets cardioprotecteurs sont obtenus via des mécanismes indépendants de la diminution de la PA, les analyses du transcriptome/miRNome cardiaque indiquent un mécanisme basé sur une diminution des processus de remodelage et d’inflammation ainsi qu’ une restauration de la fonction de métabolisme énergétique des acides gras au niveau myocardique / Mineralocorticoid Receptor Antagonists (MRA) are clinically beneficial in individuals with chronic heart failure (HF). One of the major risk factors for HF, the metabolic syndrome (MetS), has been also reported to be associated with increased aldosterone production and excessive MR activation. In this context, we hypothesized that the use of MRA could be applied to target the MetS features and prevent the subsequent progression towards HF. In this project, Spontaneously Hypertensive Heart failure rats (SHHF) carrying or not a mutation in the leptin receptor (« cp ») leading to MetS development (SHHFcp/cp and SHHF+/+respectively) were used as experimental model. Animals from both genotypes were given either the selective MRA (Eplerenone, Eple) or placebo from 1.5 to 12.5 months of age and their metabolic and cardiovascular parameters were regularly monitored. The molecular functions altered in the heart and visceral adipose tissues as MetS develops and progresses towards HF as well as those modulated by Eple action were characterized by the analysis of animal’s transcriptome and miRNome. Our data showed that SHHFcp/cp exbiting MetS developed at 12.5 months of age eccentric cardiac hypertrophy associated with left ventricular (LV) dilatation and reduced ejection fraction (EF) as compared to SHHF+/+. While Eple did not induced differences in metabolic and cardiovascular phenotypes in SHHF+/+ rats, Eple-SHHFcp/cp had lower body weight gain and less dyslipidemia. Without effects on blood pressure (BP) and adipose transcriptome and miRNome, Eple-SHHFcp/cp rats had lower LV dilatation and hypertrophy, higher ejection fraction, isovolumic relaxation time and E/A ratio. Transcriptome and miRNome analysis of cardiac tissues revealed that Eple markedly reduced the expression of several genes involved in cardiac remodeling and inflammatory processes and increased the expression of genes related to cardiac fatty acid oxidation and metabolism. The integration and the bioinformatic exploration of transcriptome and miRNome expression profiles allowed the construction of gene regulatory networks potentially involved in the physiopathological mechanisms occuring in the SHHFcp/cp rats and those impacted by the treatment. Altogether, our data demonstrated that treatment with Eple during MetS development attenuated SHHFcp/cp weight gain and dyslipidemia contributing to the amelioration of their cardiac structural and functional parameters. Interestingly, those beneficial cardioprotective effects were obtained via mechanisms independent of BP lowering, the analysis of cardiac transcriptome/miRnome revealed that Eple may have acted by depressing cardiac remodeling and inflammatory processes and restoring the function of fatty acid metabolism in the myocardium

L'obésité, un problème de santé mondial, est associée à des comorbidités telles que le syndrome métabolique, la stéato-hépatite non alcoolique, la cardiomyopathie métabolique etc. Leur incidence et développement peuvent être le résultat des interactions gènes-environnement. Ces dernières années, une série d’études expérimentales et cliniques ont montré l’implication de donneurs de méthyles dans ces pathologies via la programmation fœtale. Notre travail a évalué, à la fois le rôle de donneurs de méthyles et le profil métabolique dans une population d’obèses, puis sur un modèle animal de ratons avec une carence en donneurs de méthyles, soumis à la vie adulte à un régime hyper-énergétique. Chez l’homme, nous avons démontré qu’une carence en vitamine B12 associée à un excès de folates est liée à l’insulino-résistance. Puis, nous avons observé des anomalies du métabolisme des acides gras. Chez l’animal, nous avons montré que la carence en donneurs de méthyles provoque une hypertension artérielle systémique et une fibrose cardiaque, surtout chez les femelles. Par contre, chez les mâles, nous avons observé une stéatose hépatique dans le groupe des rats mâles carencés et soumis à un régime hyper-énergétique. En conclusion, la carence en donneurs de méthyles est associée aux maladies chronico-dégénératives. / Obesity, is global health problem, is associated with comorbidities such as metabolic syndrome, nonalcoholic steatohepatitis, metabolic cardiomyopathy etc. Their incidence and development may be the result of gene-environment interactions. In the last years, the experimental and clinical studies have shown the involvement of methyl donors in these pathologies via « fetal programming ». Our work has evaluated the role of methyl donor on metabolic profile in obese subjects, and also in an animal model of pups with a deficiency of methyl donors, subject to high-fat diet in adulthood. In humans, we have demonstrated that vitamin B12 deficiency associated with excess in folates, is linked to insulin resistance. Also the methyl donors have an influence on fatty acid metabolism. In animals, we have shown that deficiency of methyl donors causes systemic hypertension and cardiac fibrosis, especially in females. In contrast, the males methyl donor deficient with a high fat diet had an important steatosis. In conclusion, the methyl donor shortage is associated with chronic degenerative diseases.

The purpose of this study was to determine if resistance exercise altered peripheral BDNF concentration. Eighteen trained male subjects were split into two groups performing varied repetition ranges. DUP-HR and DUP-LR groups trained 3x/week for 8 weeks, and were equated for total volume (repetitions X sets X intensity). Plasma BDNF and interleukin-6 (IL-6) levels were measured prior to and immediately following the first exercise session of weeks 1, 2, 4 and 6. Pre-exercise levels were also assessed prior to the second and third sessions of week 1 and 6. Lastly, resting levels were measured before and after training intervention. No group differences (p>0.05) were detected for either biomarker. An acute BDNF elevation (p=0.018) was detected only in the final week of training. IL-6 elevations were detected at all acute measurements (p<0.01). BDNF and IL-6 percentage change correlated significantly (p<0.05) in week-1. No chronic alterations were observed (p>0.05). / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2015 / FAU Electronic Theses and Dissertations Collection

Obesity is associated with elevated levels of the pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), contributing to systemic insulin resistance. Fibroblast growth factor 21 (FGF21) is a vital metabolic and inflammatory regulator, however circulating FGF21 concentrations are elevated in obese individuals. Acute aerobic exercise increases systemic FGF21 in normal-weight individuals, however the effect of acute aerobic exercise on plasma FGF21 response and the relationships with inflammation (IL-6 and TNF-α), insulin resistance, and energy expenditure in obese individuals is unknown. Following 30 minutes of treadmill running at 75% VO2max, plasma FGF21 response, as indicated by area-under-the-curve “with respect to increase” (AUCi) analyses, was attenuated in 12 obese compared to 12 normalweight subjects. Additionally, FGF21 AUCi positively correlated with glucose AUCi, total relative energy expenditure, and relative VO2max, suggesting that cardiorespiratory fitness levels may predict FGF21 response, contributing to the enhanced regulation of glucose and energy metabolism. / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2014. / FAU Electronic Theses and Dissertations Collection

BDNF is a neurotrophin that enhances neural health and is increased by exercise. PURPOSE: To compare moderate continuous (MCE) and high-intensity interval exercise (HIE) effects on serum BDNF levels, and examine the relationship between BDNF and lactate. METHODS: Seven males completed a VO2peak test and two protocols on separate days, (MCE) 28 min at 60% Workrate max (WRmax) and (HIE) 28 min of intervals at 90%WRmax (10- 1 min intervals separated by 2 min of rest). Serum BDNF and lactate were determined prior, during, and following both protocols. RESULTS: BDNF levels (pg/mL) increased from baseline during HIE and MCE (p<.05). The BDNF response to HIE correlated with lactate for area under the curve (AUC) (r=0.901; P<0.05). CONCLUSION: HIE is an effective alternative to MCE at increasing BDNF. Additionally, lactate may act as a measure of intensity or a mediator of the BDNF response to exercise. / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2014. / FAU Electronic Theses and Dissertations Collection

The purpose of this study was to examine the acute and temporal response of CK- MM and FGF-21 to 3-day/wk. different repetition-range, volume-equated resistance training programs over 8-weeks in previously trained males. Sixteen trained, college- aged males were counterbalanced into high (DUP-HR) or low (DUP-LR) repetition groups. Subjects performed the squat and bench press 3x/wk. for 8 weeks. Blood samples were collected at various intervals throughout the study. Trained individuals did not elicit significant acute or chronic changes in CK-MM or FGF-21 following training and the lack of change was present in both groups. Additionally, neither biomarker correlated with changes in 1RM strength. There was a very strong correlation between acute mean (r=0.95) and acute percentage change (r=0.97) increase from pre training to post training in week #1. Additionally, a moderate correlation in percentage change was observed (r=0.59) of both biomarkers from pre training to 48 hours post training in week #2. / Includes bibliography. / Thesis (M.S.)--Florida Atlantic University, 2015 / FAU Electronic Theses and Dissertations Collection

Made available in DSpace on 2016-03-22T17:27:34Z (GMT). No. of bitstreams: 1 Rafaela Bulow Bergmann.pdf: 1551363 bytes, checksum: 5175c2d3946e786b40017d62f40a91c3 (MD5) Previous issue date: 2014-09-16 / This dissertation presents a study that aimed to evaluate for the first time the association between metabolic syndrome (MetS) and breast cancer (BC) in southern Brazil, using the definitions from the National Cholesterol Education Program - Adult Treatment Panel III (NCEP-ATP III) and International diabetes Federation (IDF) for the syndrome. It is a case-control study nested in a cohort, conducted between December 2013 and August 2014 in the oncology department of the Teaching Hospital of the Federal University of Pelotas (UFPel), the Radiotherapy and Oncology Center of Santa Casa de Misericordia of Pelotas and Gynecology Abulatory (UFPel), whose attendance is from the Unified Health System (SUS). For each newly diagnosed BC case, prior to treatment, a control matched for age (± 5 years) and menopausal status was included. Women who agreed to participate (n = 164) were interviewed and asked to make a blood test including fasting glucose, HDL-cholesterol and triglycerides. Participants were also evaluated for blood pressure and waist circumference (WC). According to the NCEP ATP III MetS was diagnosed in the presence of three of five factors: blood pressure &#8805; 130/85 mmHg (or hypertension), WC &#8805; 88 cm, HDL-cholesterol <50 mg/dl (or medication), triglycerides &#8805; 150 mg/dl (or medication), and fasting glucose > 110mg/dl (or type II diabetes). Considering the IDF consensus, MetS was identified by essential presence of abdominal obesity (WC &#8805; 80 cm), in addition of two other alterations: blood pressure &#8805; 130/85 mmHg (or hypertension), HDL-cholesterol <50 mg/dl (or medication ), triglycerides &#8805; 150 mg/dl (or medication) and fasting glucose > 100 mg/dl (or type II diabetes). Cases showed a larger number of altered components of the syndrome than wemen belonging to the control group, regardless of the criteria used, and the controls were more likely to have zero, one or two metabolic abnormalities (P <0.001). According to NCEP ATP III criteria, the presence of three altered components of MetS was associated with a 7.2 times greater risk of BC compared to no alterations (95% CI: 1.97, 26.11), while the odds ratio for the IDF criteria corresponded to 10:08 (95% CI: 1.82, 55.91). The odds for having BC was 4.7 times higher in women diagnosed with MetS, regardless of the definition used (NCEP ATP III: 95% CI: 2.14, 10.23; IDF: 95% CI: 2.13, 10.17 ). Low HDL-cholesterol was related to BC risk (OR = 2.88, 95% CI: 1:47, 5.67) as well as systolic blood pressure (OR = 7.3, 95% CI: 2:43; 21.91), diastolic blood pressure (OR = 4:56; 95% CI: 1.82; 11:44) and WC &#8805; 80cm (OR = 2.1 95% CI: 1.03; 4:42). The results indicated that there was a strong relationship between MetS and risk of BC among women from southern Brazil, through both NCEP ATP III and IDF criteria. Although more studies are needed, MetS may be a promising target for future interventions aiming BC prevention / Esta dissertação expõe um estudo que objetivou avaliar pela primeira vez a associação entre a síndrome metabólica (SM) e câncer de mama (CM) no Sul do Brasil, utilizando as definições do National Colesterol Education Program - Adult Treatment Panel III (NCEP-ATP III) e International diabetes Federation (IDF) para a síndrome. Trata-se de um estudo do tipo caso-controle aninhado a uma coorte, realizado entre dezembro de 2013 e agosto de 2014 no setor de oncologia do Hospital Escola da Universidade Federal de Pelotas (UFPel), no Centro de Radioterapia e Oncologia da Santa Casa de Misericórdia de Pelotas e no Ambulatório de Ginecologia da UFPel, cujos atendimentos se dão através do Sistema Único de Saúde (SUS). Para cada caso recém diagnosticado de CM, prévio ao tratamento, um controle pareado em idade (± 5 anos) e fase da menopausa foi incluido. As mulheres que aceitaram participar (n=164) foram entrevistadas e convidadas a fazer um exame de sangue incluindo glicemia de jejum, HDL-colesterol e triglicerídeos. Participantes também foram avaliadas quanto aos níveis de pressão arterial e circunferência da cintura (CC). Segundo o critério NCEP ATP III, a SM foi diagnosticada na presença de três dos cinco fatores: pressão arterial &#8805; 130/85 mmHg (ou hipertensão), CC &#8805; 88 cm, HDL-colesterol < 50 mg/dl (ou medicação), triglicerideos &#8805; 150 mg/dl (ou medicação), e glicose de jejum > 110mg/dl (ou diabetes tipo II). Considerando o consenso IDF, a SM foi identificada pela presença essencial de obesidade abdominal (CC &#8805; 80 cm), em adição a duas outras alterações: pressão arterial &#8805; 130/85 mmHg (ou hipertensão), HDL-colesterol < 50 mg/dl (ou medicação), triglicerideos &#8805; 150 mg/dl (ou medicação) e glicemia de jejum > 100 mg/dl (ou diabetes tipo II). O grupo de casos demonstrou um maior número de componentes da síndrome alterados do que aquelas que pertenciam ao grupo controle, independentemente do critério utilizado, e os controles foram mais propensos a ter zero, uma ou duas alterações metabólicas (P < 0.001). De acordo com o critério NCEP ATP III, a presença de três componentes alterados da SM foi associado a um risco 7,2 vezes maior de CM em relação a ausência de alterações (IC95%: 1,97; 26,11), sendo que para o critério IDF a razão de chances correspondeu a 10.08 (IC95%:1.82; 55.91). A probabilidade de ter CM foi 4,7 vezes maior em mulheres com diagnóstico de SM, independentemente da definição utilizada (NCEP ATP III: IC95%: 2,14; 10,23; IDF: IC95%: 2,13; 10,17). Baixo HDL-colesterol foi relacionado ao risco de CM (OR=2.88; 95%CI: 1.47; 5.67), bem como a pressão arterial sistólica (OR=7.3; 95%CI: 2.43; 21.91), diastólica (OR=4.56; 95%CI: 1.82; 11.44) e CC &#8805; 80cm (OR=2.1 95%CI: 1.03; 4.42). Os resultados obtidos indicaram que houve uma forte relação entre SM e risco de CM entre as mulheres do Sul do Brasil, tanto através do critério NCEP ATP III quanto IDF. Apesar de mais estudos serem necessários, a SM pode ser um alvo promissor para futuras intervenções almejando a prevenção do CM